Early patient identification enables critical intervention
to help improve fibrosis and avoid severe outcomes like cirrhosis1,2

Proactive Management Early Patient Identification

An optimal approach for managing MASH with significant fibrosis (F2/F3) requires comprehensive management3

Halting or reversing fibrosis

To help maximize histologic improvements in fibrosis, inflammation, and steatosis, therapeutic options should directly target the liver dysfunction that drives disease progression and increases the risk of liver-related consequences.2,4,5

See the latest AASLD practice guidance update for patients with MASH with fibrosis stage F2/F3

Lifestyle modifications

A comprehensive approach to diet and exercise includes restriction of energy consumption, focus on macronutrient composition, reduction of fructose and daily alcohol intake, and an increase in physical activity.2,3

Managing comorbidities

To improve overall patient health, it is important to manage and control any comorbidities that may be present.2

Learn about a management option that targets a pathway responsible for liver dysfunction and fibrosis progression

Discover a management option

Identify patients at risk of MASH with significant fibrosis in your practice
with a proactive, systematic screening2,3

The below approach can help evaluate fibrosis risk and identify patients who may be appropriate for active management2

1

Identify high-risk
patients with:

2

Primary risk assessment:
FIB-4

3

Secondary risk
assessment: VCTE or ELF

4

Management

Fib-4 ranges of risk
VCTE, kPa and ELF ranges of risk
Management recommendations per risk.

  • Other NITs such as MRI-PDFF or MRE may be useful for identifying MASH patients with moderate to advanced fibrosis2,6

  • In some cases, a liver biopsy should be considered when there is diagnostic uncertainty, as may occur with discordant or indeterminate NITs2

Defuse the threat of fibrosis progression and liver-related
consequences for patients with MASH with significant fibrosis2

Discover a management option

*>30 U/L for ≥6-12 months.2 

AASLD=American Association for the Study of Liver Diseases; AST=aspartate aminotransferase; ALT=alanine aminotransferase; ELF=enhanced liver fibrosis; FIB-4=Fibrosis-4; kPa=kilopascal; MASH=metabolic dysfunction-associated steatohepatitis; MRE=magnetic resonance elastography; MRI-PDFF=magnetic resonance imaging proton density fat fraction; NIT=noninvasive test; VCTE=vibration-controlled transient elastography.

References: 1. Fishman JC et al. J Manag Care Spec Pharm. 2024;30(9)(article and suppl):929-941. 2. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. 3. Kanwal F et al. Gastroenterology. 2021;161(5):1657-1669. 4. Karim G, Bansal MB. touchREV Endocrinol. 2023;19(1):60-70. 5. Wang GY et al. World J Gasteroenterol. 2023;29(1):75-95. 6. Ajmera V, Loomba R. Mol Metab. 2021;50:101167.